helicas
import
class
enzym
unwind
doublestrand
nucleic
acid
singlestrand
one
use
energi
nucleosid
triphosph
ntp
hydrolysi
implic
viru
replic
cellular
process
requir
singlestrand
nucleic
acid
includ
dna
replic
repair
transcript
critic
role
viral
replic
prolifer
helicas
target
therapi
mani
viral
diseas
fact
viral
helicas
inhibitor
shown
success
drug
candid
treatment
hepat
c
herp
simplex
viru
infect
therefor
develop
simpl
fast
costeffect
platform
import
assay
nucleic
acid
unwind
activ
helicas
convent
method
assess
dna
rna
unwind
activ
helicas
involv
substrat
doublestrand
nucleic
acid
one
radiolabel
p
degre
substrat
unwind
helicas
estim
use
polyacrylamid
gel
electrophoresi
page
subsequ
visual
radioisotop
howev
convent
assay
timeconsum
ineffici
lengthi
prepar
time
radiolabel
substrat
limit
shelf
life
run
page
addit
assay
method
assum
unwound
singlestrand
dna
ssdna
undergo
reanneal
complementari
strand
reanneal
doublestrand
dna
dsdna
consist
trap
dna
previous
unwound
complementari
dna
particip
helicas
reaction
substrat
overal
convent
assay
method
adequ
multipleturnov
helicas
reaction
parallel
activ
screen
date
sever
strategi
assay
helicas
activ
develop
base
enzymelink
immunosorb
assay
elisa
fluoresc
reson
energi
transfer
fret
chemiluminesc
newer
approach
partli
overcom
limit
convent
assay
still
possess
undesir
featur
high
cost
labori
procedur
prohibit
routin
implement
herein
report
platform
assay
helicas
unwind
activ
reli
preferenti
bind
graphen
oxid
go
ssdna
dsdna
therebi
quench
fluoresc
dye
conjug
ssdna
previous
go
report
interact
strongli
nucleotid
pstack
interact
ring
structur
nucleobas
hexagon
cell
go
wherea
dsdna
stabli
adsorb
onto
go
surfac
effici
shield
nucleobas
within
neg
charg
phosphat
backbon
dsdna
addit
go
known
effici
quench
fluoresc
nearbi
organ
dye
helicas
assay
base
go
start
prepar
dsdna
substrat
contain
fluoresc
dye
end
one
strand
initi
helicas
reaction
helicas
ad
mixtur
dsdna
go
dsdna
exhibit
intens
fluoresc
helicaseinduc
unwind
dsdna
proce
fluoresc
decreas
strong
interact
go
unwound
ssdna
result
fluoresc
quench
go
figur
demonstr
strategi
use
sever
acut
respiratori
syndrom
coronaviru
sarscov
scv
helicas
sar
fatal
infecti
diseas
develop
flulik
symptom
high
mortal
rate
scv
helicas
recogn
potenti
target
develop
antivir
drug
sar
dsdna
substrat
scv
helicas
design
base
previou
report
first
prepar
go
accord
modifi
hummer
method
confirm
success
format
singlelay
go
sheet
prepar
go
analyz
atom
forc
microscopi
afm
sheet
width
thick
height
go
approxim
mm
sheet
larger
mm
nm
respect
figur
b
chemic
structur
go
character
ir
raman
spectroscopi
sever
characterist
peak
function
group
contain
oxygen
observ
ir
spectrum
go
includ
peak
cm
result
co
stretch
respect
figur
c
strong
dband
absorpt
cm
appear
raman
spectrum
go
figur
taken
togeth
data
support
premis
singlelay
go
sheet
success
prepar
next
use
dye
fluorescein
amidit
fam
attach
ssdna
fssdna
demonstr
fluoresc
quench
occur
upon
bind
fssdna
go
surfac
separ
mixtur
contain
go
mg
ml
either
anneal
fdsdna
fssdna
prepar
helicas
reaction
buffer
ph
buffer
contain
mm
trishcl
mm
nacl
mm
ethylenediaminetetraacet
acid
edta
mm
mgcl
glycerol
fluoresc
emiss
spectra
mixtur
measur
time
fdsdna
show
strong
fluoresc
around
nm
regardless
presenc
go
howev
mixtur
fssdna
go
show
quench
fluoresc
minut
room
temperatur
result
interact
go
ssdna
figur
dsdna
expect
repuls
interact
go
neg
charg
go
zeta
potenti
go
mv
neg
charg
phosphat
backbon
dna
quench
fluoresc
take
place
time
fdsdna
mixtur
fluoresc
reach
plateau
rel
high
level
minut
figur
b
contrast
go
quench
nearli
fluoresc
fssdna
select
interact
ssdna
compar
dsdna
experiment
condit
employ
measur
scv
helicas
activ
use
fdsdna
substrat
presenc
go
variou
concentr
helicas
mixtur
fdsdna
go
scv
helicas
reaction
buffer
contain
adenosin
atp
mm
prepar
incub
fluoresc
emiss
nm
measur
variou
time
interv
expect
degre
fdsdna
unwind
helicas
depend
helicas
concentr
figur
confirm
fluoresc
quench
result
fdsdna
unwind
helicas
concentr
atpan
energi
sourc
helicas
activitywa
vari
concentr
helicas
kept
constant
nm
helicas
activ
inde
increas
atp
concentr
rais
figur
b
next
perform
assay
helicas
inhibit
demonstr
present
method
quantit
robust
enough
gener
applic
includ
inhibitor
assay
two
compound
amppnp
doxorubicin
also
known
hydroxydaunorubicin
chosen
model
inhibitor
helicas
amppnp
nonhydrolyz
atp
analogu
previous
report
inhibit
helicas
activ
compet
atp
bind
site
doxorubicin
anticanc
agent
intercal
duplex
dna
therebi
slow
unwind
dsdna
began
reaction
mixtur
contain
helicas
nm
fdsdna
nm
go
mg
ml
atp
mm
variou
concentr
inhibitor
helicas
reaction
buffer
case
doxorubicin
mixtur
fdsdna
doxorubicin
prepar
incub
minut
room
temperatur
prior
mix
reagent
ensur
intercal
doxorubicin
fdsdna
without
interfer
compon
chang
fluoresc
intens
nm
measur
minut
reaction
mixtur
half
maxim
inhibitori
concentr
ic
valu
amppnp
doxorubicin
found
mm
respect
figur
b
perform
highthroughput
screen
inhibitor
would
effici
abl
measur
helicas
activ
fluoresc
imag
multiwel
plate
contain
multipl
reaction
mixtur
demonstr
feasibl
parallel
assay
inhibit
assay
carri
plate
minut
fluoresc
imag
obtain
reaction
mixtur
plate
use
ivi
imag
system
xenogen
alameda
ca
usa
inhibit
helicas
activ
amppnp
doxorubicin
clearli
visual
dose
depend
distinctli
observ
fluoresc
imag
figur
c
final
perform
convent
helicas
assay
use
plabel
dsdna
direct
comparison
present
assay
plabel
dsdna
substrat
first
prepar
use
p
atp
polynucleotid
kinas
follow
anneal
accord
establish
procedur
reaction
mixtur
contain
plabel
dsdna
nm
helicas
nm
trap
dna
mm
prepar
reaction
buffer
trap
dna
unlabel
bottomstrand
dna
requir
excess
prevent
reanneal
unwound
label
dna
product
aliquot
taken
minut
quench
ad
quench
buffer
mm
edta
ph
sodium
dodecyl
sulfat
vv
glycerol
bromophenol
blue
analyz
immedi
electrophoresi
nondenatur
polyacrylamid
gel
figur
top
control
heatdenatur
dna
prepar
presenc
trap
dna
includ
gel
gel
imag
obtain
phosphorimag
give
rel
amount
dsdna
ssdna
sampl
basic
gelbas
assay
endpoint
assay
analyz
reaction
termin
featur
make
gelbas
assay
inappropri
realtim
kinet
studi
data
also
illustr
requir
trap
dna
figur
dosedepend
inhibit
helicas
reaction
carri
use
gobas
method
b
inhibit
helicas
amppnp
nonhydrolyz
atp
deriv
b
doxorubicin
anthracyclin
anticanc
agent
observ
ic
valu
obtain
c
fluoresc
imag
reaction
mixtur
helicas
fdsdna
go
obtain
absenc
presenc
inhibitor
imag
first
row
show
duplexdna
unwind
depend
helicas
concentr
quantit
inhibit
assay
also
perform
amppnp
doxorubicin
use
fluoresc
imag
demonstr
highthroughput
assay
readili
feasibl
second
third
row
figur
comparison
convent
pbase
helicas
assay
gobas
assay
nativegel
shift
assay
helicas
unwind
dsdna
substrat
perform
resolv
unwound
dna
nativ
page
visual
phosphorimag
lane
substrat
dsdna
lane
heatdenatur
control
lane
unwind
reaction
min
lane
unwind
reaction
min
data
illustr
requir
trap
dna
convent
assay
pagebas
assay
kind
endpoint
assay
wherea
gobas
assay
perform
real
time
top
gobas
assay
helicas
unwind
dsdna
substrat
perform
comparison
convent
assay
bottom
fluoresc
complet
quench
within
min
b
inhibit
helicas
amppnp
quantit
measur
helicas
concentr
chang
gobas
assay
made
helicas
inhibit
kinet
straightforward
sinc
assay
base
quantit
realtim
measur
equal
time
period
unwind
exhibit
amount
unwound
product
ssdna
presenc
versu
absenc
trap
dna
contrast
present
gobas
method
figur
bottom
show
unwind
dsdna
complet
within
minut
similar
condit
even
absenc
trap
dna
result
indic
gobas
method
substanti
condit
prevent
reanneal
unwound
ssdna
captur
displac
ssdna
effici
reanneal
unwound
ssdna
caus
less
accumul
ssdna
product
given
time
perform
presenc
appropri
trap
molecul
thu
absenc
trap
dna
adequ
reflect
accumul
ssdna
product
importantli
convent
gelbas
dna
unwind
assay
simpli
allornon
method
report
complet
unwound
ssdna
product
wherea
go
method
report
progress
dsdna
unwind
real
time
excess
trap
dna
need
precis
measur
convent
assay
method
cost
assay
increas
substanti
thu
hamper
use
parallel
assay
multipl
sampl
contrast
present
method
fluorescencebas
assay
monitor
real
time
variou
reaction
condit
illustr
power
method
kinet
helicas
inhibit
amppnp
inhibitor
measur
follow
fluoresc
intens
function
time
reaction
mixtur
contain
variou
concentr
helicas
amppnp
base
assay
method
rel
rate
unwind
dsdna
helicas
could
calcul
figur
b
gobas
assay
platform
allow
quantit
measur
helicas
activ
real
time
thu
make
applic
studi
helicas
inhibit
kinet
convent
gelbas
assay
conclus
develop
new
gobas
platform
assay
duplexdna
unwind
activ
best
knowledg
work
first
util
go
enzym
activ
assay
gobas
platform
sever
advantag
convent
method
first
helicas
activ
monitor
real
time
follow
chang
fluoresc
without
requir
addit
step
reagent
second
gobas
assay
costeffect
compar
convent
assay
demand
expens
isotop
label
trap
dna
go
critic
compon
present
method
prepar
larg
quantiti
graphit
avail
low
cost
third
prepar
go
much
longer
shelf
life
p
halflif
day
ambient
condit
go
store
month
form
suspend
aqueou
solut
consider
longer
powder
form
fourth
present
method
make
highthroughput
screen
feasibl
shown
figur
fluoresc
imag
multipl
sampl
make
possibl
parallel
assay
without
need
purif
resolv
step
therefor
platform
easili
appli
highthroughput
analysi
system
expect
method
readili
applic
research
involv
duplexdna
unwind
screen
helicas
inhibitor
drug
candid
antiviru
therapi
studi
benefit
method
quantit
costeffect
technic
simplic
go
sheet
prepar
accord
previous
report
method
sarscov
helicas
overexpress
escherichia
coli
purifi
describ
previous
upperstrand
dna
ml
mm
ttt
ttt
ttt
ttt
ttt
gag
cgg
att
act
ata
cta
cat
tag
aat
genotech
seoul
korea
fluorescentdyeconjug
bottomstrand
dna
ml
mm
att
cta
atg
tag
tat
agt
aat
ccg
genotech
mix
anneal
ph
buffer
contain
mm
trishcl
mm
nacl
buffer
substrat
solut
prepar
mix
anneal
substrat
mm
edta
mm
biorad
hercul
ca
usa
atp
disodium
mm
sigmaaldrich
st
loui
mo
usa
mgcl
mm
junsei
tokyo
japan
buffer
contain
glycerol
solut
go
solut
prepar
buffer
mg
ml
substrat
solut
ml
go
solut
ml
mix
helicas
reaction
initi
addit
variou
amount
helicas
stock
solut
nm
addit
helicas
fluoresc
intens
measur
use
synergi
mx
fluoromet
biotek
potton
uk
nm
min
keyword
biosensor
dna
fluoresc
spectroscopi
graphen
virus
